Leibowitz Arleen A, Sood Neeraj
UCLA School of Public Affairs, 3250 Public Policy Building, Los Angeles, CA 90095-1656, USA.
Int J Health Care Finance Econ. 2007 Mar;7(1):59-71. doi: 10.1007/s10754-007-9012-0. Epub 2007 May 5.
We examine whether U.S. states can use their market power to reduce the costs of supplying prescription drugs to uninsured and underinsured persons with HIV through a public program, the AIDS Drug Assistance Program (ADAP). Among states that purchase drugs from manufacturers and distribute them directly to clients, those that purchase a greater volume pay lower average costs per prescription. Among states depending on retail pharmacies to distribute drugs and then claiming rebates from manufacturers, those that contract with smaller numbers of pharmacy networks have lower average costs. Average costs per prescription do not differ between the two purchase methods.
我们研究了美国各州是否能够利用其市场力量，通过一项公共项目——艾滋病药物援助计划（ADAP），来降低向未参保和保险不足的艾滋病毒感染者供应处方药的成本。在那些从制造商处购买药物并直接分发给客户的州中，购买量较大的州每张处方的平均成本较低。在那些依靠零售药店分发药物然后向制造商索取回扣的州中，与较少数量的药房网络签约的州平均成本较低。两种购买方式下每张处方的平均成本没有差异。
